Advisornet Financial’s Myriad Genetics MYGN Stock Holding History

Advisornet Financial’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12	Closed	-$230	–	2348
2023 Q4	$230	Buy	12 +11	+1,100%	+$190	﹤0.01%	2275
2023 Q3	$16	Sell	1 -9	-90%	-$171	﹤0.01%	2270
2023 Q2	$232	Buy	10 +2	+25%	+$44	﹤0.01%	2202
2023 Q1	$186	Buy	+8	New	+$162	﹤0.01%	2257
2018 Q4	–	Sell	-16	Closed	-$1K	–	1538
2018 Q3	$1K	Buy	+16	New	+$711	﹤0.01%	1417

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advisornet Financial's MYGN Position: Q1 2024 in Review

Advisornet Financial sold out of Myriad Genetics (MYGN) in Q1 2024, closing a stake of 12 shares — an estimated $230 sold.

Advisornet Financial first reported a position in MYGN in Q3 2018 and held it in 5 quarters. The position peaked at $1K in Q3 2018. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.

Advisornet Financial reported no remaining Myriad Genetics position as of Q1 2024 after selling out during the quarter.
Advisornet Financial sold 12 Myriad Genetics shares in Q1 2024, an estimated $230.
Advisornet Financial first reported a position in Myriad Genetics in Q3 2018 and held it in 5 quarters.
Advisornet Financial's Myriad Genetics position peaked at $1K in Q3 2018.
186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.

Based on Advisornet Financial's 13F filing for Q1 2024, filed 12 Apr 2024.